144 related articles for article (PubMed ID: 35900770)
1. Serum levels of neuron-specific enolase as a prognostic factor for disease progression in patients with GET/NEN in the pancreas and the small intestine.
Fuksiewicz M; Kowalska M; Kolasinska-Cwikla A; Kotowicz B
Endocr Connect; 2022 Sep; 11(9):. PubMed ID: 35900770
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.
Fuksiewicz M; Kowalska M; Kolasińska-Ćwikła A; Ćwikła JB; Sawicki Ł; Roszkowska-Purska K; Drygiel J; Kotowicz B
Endocr Connect; 2018 Jun; 7(6):803-810. PubMed ID: 29724794
[TBL] [Abstract][Full Text] [Related]
3. Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues.
Gut P; Czarnywojtek A; Sawicka-Gutaj N; Woliński K; Maciejewski A; Komarnicki P; Ruchała M
Endokrynol Pol; 2021; 72(4):308-318. PubMed ID: 34292567
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms.
Kidess E; Giesecke Y; Eichhorn I; Mohr R; Jann H; Fischer C; Wiedenmann B; Roderburg C; Tacke F; Sigal M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10925-10933. PubMed ID: 37318593
[TBL] [Abstract][Full Text] [Related]
6. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
[TBL] [Abstract][Full Text] [Related]
7. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects.
Isgrò MA; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():125-43. PubMed ID: 26530364
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.
Yan P; Han Y; Tong A; Liu J; Wang X; Liu C
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34286335
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
10. Role of the ratio of NSE serum concentration in evaluating the therapeutic effect on metastatic neuroendocrine neoplasms of the liver.
Kan J; Tian Y; Shao Y; Xu H; Li X; Tang Q
Tumori; 2022 Apr; 108(2):157-164. PubMed ID: 33759643
[TBL] [Abstract][Full Text] [Related]
11. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Suh KJ; Keam B; Kim M; Park YS; Kim TM; Jeon YK; Kim DW; Chung DH; Kim YW; Heo DS
Clin Lung Cancer; 2016 Jul; 17(4):245-252.e1. PubMed ID: 26719155
[TBL] [Abstract][Full Text] [Related]
12. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs.
Lv Y; Han X; Zhang C; Fang Y; Pu N; Ji Y; Wang D; Xuefeng X; Lou W
Endocr Connect; 2018 Jan; 7(1):169-178. PubMed ID: 29191920
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
[TBL] [Abstract][Full Text] [Related]
14. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
Pujol JL; Boher JM; Grenier J; Quantin X
Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
[TBL] [Abstract][Full Text] [Related]
16. Serum neuron specific enolase levels correlate with patient prognosis for advanced lung cancer.
Xue F; Zhu L; Wang L; Wang Q
Int J Clin Exp Med; 2015; 8(6):9498-504. PubMed ID: 26309614
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
18. Serum neuron-specific enolase levels are upregulated in patients with acute lymphoblastic leukemia and are predictive of prognosis.
Liu CC; Wang H; Wang JH; Wang L; Geng QR; Chen XQ; Lu Y
Oncotarget; 2016 Aug; 7(34):55181-55190. PubMed ID: 27409171
[TBL] [Abstract][Full Text] [Related]
19. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase.
Simpson S; Vinik AI; Marangos PJ; Lloyd RV
Cancer; 1984 Oct; 54(7):1364-9. PubMed ID: 6088026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
